Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Custom Head‑to‑Tail Cyclic Peptide Synthesis

Backbone macrocyclization (N→C) for stable, conformationally defined cyclic peptides — built for drug discovery, receptor ligands, protease-resistant scaffolds and SAR studies.

Request a Quote Speak to a Scientist
Talk to a chemist Request a quote
Overview Services Specs & deliverables Cyclization types Design guide How to choose Contact

Overview

We synthesize head‑to‑tail cyclic peptides (also called backbone‑cyclized or N‑to‑C macrocycles) with practical ring‑closure strategy, purification, and fit‑for‑purpose QC—optimized for drug discovery, receptor ligands, protease‑resistant tools, and structure‑activity studies.

A head-to-tail cyclic peptide is a peptide whose N-terminus and C-terminus are linked by an amide bond (N→C cyclization), creating a closed backbone ring that often increases protease resistance and conformational control.

N‑terminus ↔ C‑terminus ring closure HPLC/UPLC purification LC‑MS identity 45+ Years of Expertise U.S. Facilities - Texas
What is head‑to‑tail cyclization?

Head‑to‑tail cyclization forms an intramolecular amide bond between the N‑terminal amine and the C‑terminal carboxyl, producing a backbone macrocycle (N→C). Unlike disulfide loops, the ring is covalent and non‑reducible.

Common synonyms: backbone cyclization, N‑to‑C cyclization, N→C macrocycle, head‑to‑tail cyclic peptide, cyclic backbone peptide.

head‑to‑tail cyclic peptide synthesis backbone cyclization macrocyclic peptide N→C ring closure
Why head‑to‑tail?
  • Protease resistance: blocks exopeptidase attack by removing free termini.
  • Conformational control: reduces flexibility, often increasing binding affinity/selectivity.
  • Cleaner topology: no external linker; “native‑like” backbone connectivity.
  • Better assay robustness: improved stability in serum/cell media (sequence‑dependent).

Not every sequence cyclizes efficiently. We can help tune length, turn propensity, and terminal accessibility to favor intramolecular closure while minimizing oligomerization.

Related pages: Peptide cyclization, Stapled peptides, Difficult peptide synthesis, Click chemistry peptides.

Head‑to‑tail cyclization schematic

Linear precursor → N→C macrocycle

The key reaction is intramolecular amide bond formation. We typically cyclize a side‑chain‑protected linear precursor under dilute conditions to favor ring closure over dimerization/oligomerization.

If your design also needs a second constraint (e.g., disulfide/lactam), we can combine head‑to‑tail cyclization with side‑chain chemistry to create bicyclic or multi‑constrained scaffolds.

What we optimize (real‑world)
  • Precursor topology: orthogonal protection and terminal accessibility
  • Ring‑closure conditions: solvent system, activation chemistry, additives
  • Conformation bias: turn‑friendly motifs that bring ends together
  • Side reactions: suppress dimerization/oligomerization; minimize epimerization
  • Purification plan: anticipate retention changes vs linear precursor
Request a Quote Cyclization design guide

Tip for quoting: send your sequence, intended topology (head‑to‑tail vs side‑chain), quantity/purity targets, and whether termini must be free/capped before cyclization.

Benefits (why head‑to‑tail is often the “cleanest” macrocycle)

Stability

Blocks exopeptidase cleavage and often increases overall protease resistance.

Affinity & selectivity

Reduced flexibility can lower the entropic penalty on binding and improve target selectivity (sequence‑dependent).

Assay robustness

More stable reagents for serum exposure, receptor assays, and enzyme studies—helpful for reproducibility.

No linker baggage

Pure N→C closure; avoids extra atoms from external linkers used in some cyclization strategies.

Scaffold for tuning

Can be combined with N‑methylation, D‑residues, or side‑chain constraints for permeability/stability optimization.

Better structure control

Improves conformational definition, useful for SAR studies and structure‑guided design.

Services we provide

N‑to‑C cyclization backbone macrocycle high dilution

Synthesis of a protected linear precursor followed by intramolecular N‑terminus to C‑terminus ring closure under controlled activation conditions. Purification and QC tailored to your purity/quantity requirements.

difficult peptide synthesis hydrophobic peptides route optimization

For sequences prone to aggregation or low solubility, we can adjust resin choice, coupling strategy, temporary solubilizing approaches, and cyclization conditions to improve intramolecular closure yields.

Tip: tell us your failure mode (poor crude purity, insoluble precursor, oligomers) so we can prioritize the right mitigation.

bicyclic peptides disulfide side‑chain lactam

Combine head‑to‑tail macrocyclization with a second constraint to increase rigidity or control surface presentation. This can be valuable for antimicrobial scaffolds and receptor ligands that benefit from a defined topology.

click‑ready cyclic peptide biotinylation fluorescent labels

Add site‑defined labels or click handles (azide/alkyne/DBCO) for pull‑downs, imaging, and conjugation while preserving the backbone macrocycle.

N‑methylation D‑amino acids non‑natural residues

For permeability or stability tuning, we can incorporate selected backbone modifications (sequence‑dependent) and deliver matched panels for SAR.

Where head‑to‑tail cyclic peptides are used
  • Receptor ligands (GPCR and beyond)
  • Enzyme inhibitors
  • Protein–protein interaction (PPI) modulators
  • Antimicrobial peptides & constrained scaffolds
  • Epitope stabilization / structural probes
  • Target engagement tools
  • Lead optimization (SAR panels)
  • Conjugation-ready macrocycles
  • Protease-resistant research reagents

Specifications & typical deliverables

Typical deliverables
  • Purified head‑to‑tail cyclic peptide (lyophilized)
  • Analytical HPLC/UPLC chromatogram (purity)
  • Mass confirmation by LC‑MS when feasible
  • Certificate of Analysis (COA)

If you need matched controls (linear vs cyclic, L vs D, labeled vs unlabeled), mention it up front—we’ll align the plan and QC accordingly.

Related services

Connect backbone modification with constrained scaffolds, labeling, and challenging sequences.

Peptidomimetics Macrocyclic peptides Peptide cyclization Click chemistry peptides Difficult peptide synthesis Peptide modifications
Request a Quote See Categories
How to specify your order
Item What to provide
Sequence AA sequence + any non‑standard residues, and whether termini must be free prior to cyclization
Cyclization Head‑to‑tail (N→C). If you want a second constraint, specify (disulfide, lactam, etc.)
Quantity Target amount (mg) and acceptable minimum
Purity Crude / desalted / purified (e.g., ≥90% / ≥95% / ≥98%)
Application Assay, binding, cell work, animal studies, conjugation, MS standard, etc.
QC Standard HPLC + MS (when feasible), or add application‑specific analytics as needed

Peptide cyclization types (categories) — and what they’re best for

“Cyclic peptide” can mean multiple linkage categories. The cyclization type you choose affects rigidity, stability, reversibility, synthetic risk, and whether a free terminus remains for labeling or activity. Below is a practical taxonomy and selection guide used in cyclic peptide design and custom synthesis projects.

Head-to-tail (N→C)

Backbone amide between N-terminus and C-terminus. Linker-free, “clean” topology.

  • Excellent exopeptidase resistance
  • High conformational control
  • Drug-like macrocycles / natural product mimics
Side-chain lactam

Amide bridge (e.g., Lys–Asp/Glu). Great for loop control while keeping termini free.

  • Flexible ring placement
  • Often higher practical yields
  • Conjugation-ready termini possible
Disulfide

Cys–Cys bridge. Useful for folding/structure and reversible redox behavior.

  • Reversible under reducing conditions
  • Common in hormones/toxins
  • Buffer/redox context matters
Stapled peptides

Helix-stabilizing staple (often hydrocarbon). Used in PPI targeting and cell studies.

  • Improves helicity
  • Can improve protease resistance
  • Design depends on helix register
Thioether / click closure

Non-reducible linkages (e.g., thioether, triazole) for stability or orthogonal chemistry.

  • Robust in complex conditions
  • Compatible with handle-based designs
  • Useful when disulfides are unstable
Hybrid (terminus-to-side-chain)

Balances constraint and synthetic accessibility while preserving a functional terminus if needed.

  • Good when one terminus must remain free
  • Flexible topology control
  • Often reduces oligomerization risk vs N→C

How to choose a cyclization strategy (decision matrix)

Start with your primary goal
  • Maximum protease resistance → usually head-to-tail (N→C)
  • Need free N- or C-terminus → side-chain lactam or hybrid
  • Redox-responsive loop → disulfide (validate buffer conditions)
  • Enforce α-helix (PPI) → stapling strategy
  • Non-reducible stability → thioether/click closure
  • High-throughput SAR panels → start simple (often lactam), escalate to N→C if needed

If you send your sequence and intended use, we’ll recommend a practical topology and a synthesis/QC plan aligned to your goals.

Key feasibility checks (fast)
  • Ring size & strain: very short rings may strain; very long rings may be floppy
  • Aggregation risk: hydrophobic patches can drive intermolecular coupling
  • Turn propensity: turn-friendly motifs help bring ends together
  • Functional constraints: do termini need to be free, capped, or modified?
  • Pharmacophore integrity: keep linkage away from critical binding residues

We routinely provide matched sets (linear vs cyclic, or alternative cyclization types) to support structure-activity studies.

Goal Best starting option Notes
Max stability / termini protection Head-to-tail (N→C) Linker-free macrocycle; monitor oligomers; tune solubility and turn propensity.
Keep termini free Lactam / hybrid Choose bridge location away from pharmacophore; preserves N or C terminus for labeling/conjugation.
Reversible loop Disulfide Validate in assay buffer; consider non-reducible alternatives if needed.
Helix stabilization Stapled peptide Staple position is design-critical; evaluate helicity vs activity tolerance.
Harsh-condition stability Thioether / click Robust linkage; confirm geometry and identity by LC-MS.

Head-to-tail vs side-chain cyclization (design comparison)

Schematic: backbone (N→C) closure vs side-chain bridge
Schematic: backbone (N→C) closure vs side-chain bridge
Concept schematic for clarity (not atom-accurate). Bridge placement and ring geometry are sequence-dependent.
Head-to-tail (N→C): strengths
  • No free termini → strong exopeptidase resistance
  • Linker-free → “clean” macrocycle topology
  • High conformational control → often improves affinity/selectivity
  • Strong fit for macrocyclic drug discovery and natural product mimics

Primary synthesis risk: intermolecular coupling (dimers/oligomers) if concentration is too high or the sequence aggregates. See Prevent dimerization below.

Side-chain cyclization: strengths
  • Keep termini free for labeling, conjugation, or activity requirements
  • Flexible bridge placement (choose residues to connect)
  • Often higher practical yields depending on linkage chemistry
  • Useful for loop stabilization, epitope presentation, and constrained probes

Primary design risk: bridge placement can perturb key binding residues; choose linkage away from the pharmacophore.

Feature Head-to-tail (N→C) Side-chain
Protease resistance Excellent vs exopeptidases; often strong overall stability Improved vs linear; depends on whether termini remain exposed
Rigidity High global constraint Variable; can be local loop/helix stabilization
Synthetic risk Higher risk of oligomerization (sequence-dependent) Often easier; depends on linkage chemistry
Termini available? No (closed) Yes (can preserve one or both)
Best fit Drug-like macrocycles, PPI leads, protease-resistant tools Conjugation-ready probes, epitope loops, constrained research reagents

How to prevent dimerization in cyclic peptide synthesis (troubleshooting)

The most common failure mode in head-to-tail cyclization is intermolecular coupling (dimers/oligomers). Prevention is a combination of sequence pre-organization, solubility control, and reaction engineering.

prevent_cyclic_peptide_dimerization.png
Goal: push the chemistry toward the intramolecular pathway using dilution, slow addition, solubility control, and turn-promoting sequence features.
Design levers (before chemistry)
  • Promote turn formation to bring termini together (sequence-dependent)
  • Reduce aggregation by balancing hydrophobicity hotspots
  • Choose bridge positions (for side-chain strategies) away from the pharmacophore
  • Orthogonal protection to avoid competing reactions
  • Consider matched alternatives (e.g., lactam vs N→C) for SAR
Reaction levers (during cyclization)
  • High dilution to favor intramolecular closure
  • Slow addition of precursor or activator to reduce intermolecular events
  • Solvent/additive tuning to keep precursor monomeric
  • Time control (don’t overrun once optimal conversion is reached)
  • On-resin vs solution strategy selection when appropriate
Monitoring & “what to look for”
  • LC-MS checkpoints during cyclization identify dimer/oligomer series early.
  • HPLC symptoms like broad peaks and late-eluting shoulders can indicate aggregation/oligomerization.
  • Fast iteration (adjust concentration/addition/solvent) often fixes the issue without sequence changes.

If you’ve tried cyclization elsewhere, send the method and chromatogram/MS summary—we can usually diagnose the dominant failure mode quickly.

Practical cyclization design guide

What makes cyclization succeed?
  • Right length: very short rings can be strained; very long rings can oligomerize.
  • Turn propensity: motifs that bring N and C termini together improve closure.
  • Terminal accessibility: ensure no required capping blocks the ring closure step.
  • Side‑chain protection strategy: orthogonal groups prevent side reactions during activation.
  • Sequence solubility: insoluble precursors may need route adjustment to close cleanly.
Common pitfalls (and how we mitigate)
  • Oligomers: high dilution + controlled addition + solvent choice.
  • Epimerization: select activation/conditions to minimize racemization (sequence‑dependent).
  • Low crude purity: optimize coupling strategy and precursor handling before closure.
  • Purification difficulty: anticipate retention shifts between linear and cyclic forms.
Request a Quote Send sequence for review

If you already tried cyclization elsewhere, share the method and what happened (dimer peak, broad HPLC, low recovery). That speeds up troubleshooting.

FAQ

What peptide length is best for head-to-tail cyclization?

Head-to-tail cyclization is often most straightforward in the ~6–20 residue range, but both shorter and longer macrocycles can be feasible with sequence pre-organization and optimized conditions.

Can I keep a free N-terminus or C-terminus and still cyclize?

Yes. If you need a free terminus for labeling, conjugation, or activity, consider side-chain lactamization or terminus-to-side-chain cyclization instead of N-to-C closure.

Does cyclization always improve potency?

Not always. Cyclization primarily improves stability and conformational control; potency can improve if the constrained conformation matches the bioactive form, but some sequences lose activity if key residues are distorted.

How do you tell dimerization vs incomplete cyclization?

LC-MS and analytical HPLC are used to distinguish higher-mass dimer/oligomer series from uncyclized precursor. Broad or new peaks plus mass multiples typically indicate oligomerization.

What are common causes of dimerization during head-to-tail cyclization?

High concentration, aggregation of hydrophobic sequences, insufficient turn formation to bring termini together, and overlong reaction times can all increase intermolecular coupling.

Can you do on-resin cyclization?

When appropriate, on-resin cyclization can reduce intermolecular reactions. The best choice (on-resin vs solution) depends on sequence, ring size, and protecting group strategy.

What are typical deliverables?

Typical deliverables include purified peptide, analytical HPLC chromatogram(s), MS (or HRMS) confirmation, and a COA documenting identity and purity; add-on characterization is available for specialized needs.

What information helps you quote and design fastest?

Send the sequence, preferred cyclization type (or “recommend”), target quantity/purity, any required termini/handles, and intended use so we can align synthesis and QC plans.

Is head‑to‑tail cyclization the same as “cyclic peptide”?

It’s one of the most common cyclic peptide formats. “Cyclic peptide” also includes side‑chain cyclization (disulfide, lactam, etc.) and mixed strategies. Head‑to‑tail specifically means N‑terminus joined to C‑terminus (N→C).

Can you deliver both linear and cyclic versions for comparison?

Yes—linear vs cyclic matched sets are common for SAR and stability comparisons. Tell us desired purity/quantity for each.

Do cyclic peptides always have higher activity?

Not always. Cyclization can improve stability and conformation, but activity depends on whether the macrocycle preserves the bioactive geometry and target interactions. We can help suggest design tweaks if activity is sensitive to flexibility.

What if my sequence is long or poorly soluble?

Long/hydrophobic sequences can be challenging. We may adjust the precursor strategy, solvent system, and cyclization conditions to minimize oligomers and improve recovery.

Can you add labels or click handles to a head‑to‑tail cyclic peptide?

Yes—site‑defined labels (biotin, dyes) and click handles (azide/alkyne/DBCO) can be incorporated while preserving the backbone macrocycle.

What QC do you provide?

Typical QC includes HPLC/UPLC purity and LC‑MS identity confirmation when feasible, plus a COA. If you need extra analytics (e.g., special salts, endotoxin, solubility notes), request it at quote stage.

More FAQ'sAll FAQ's

Contact & quote request

For the fastest quote, send your sequence(s), desired cyclization (head‑to‑tail N→C), purity/quantity targets, and application. We’ll recommend practical specifications and a synthesis/QC plan aligned to your goals.

Fast quote checklist
  • Sequence(s) + any non‑standard residues
  • Head‑to‑tail cyclization (N→C) + any extra constraints
  • Quantity (mg) + purity target
  • Intended use (assay, binding, cell work, conjugation)
  • Any constraints (must keep motif unchanged)
Fastest path
Request a Quote Contact us

Recommended reading

Background on cyclic peptide design, head‑to‑tail cyclization strategies, and macrocycle property tuning.

Want references focused on your target class (GPCR, enzymes, AMPs) or your cyclization length range? Tell us your use case and we’ll tailor the list.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links